Business
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain
-- New data published in Pain Physician shows significant improvement in functional outcomes with iovera° ---- Fewer iovera° patients required additional
About this update from Pacira Biosciences, Inc.
[{"type":"text","content":"-- New data published in Pain Physician shows significant improvement in functional outcomes with iovera° ---- Fewer iovera° patients required additional spine injections after 180 days ---- No treatment-related adverse events were reported -- BRISBANE, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced results from a randomized 30-patient pilot study evaluating iovera° cryoneurolysis versus radiofrequency ablation (RFA) for chronic low back pain (CLBP). The study, published in Pain Physician, the official journal of the American Society of Interventional Pain Physicians, demonstrated favorable safety, pain reduction, and functional disability outcomes for patients treated with iovera° over a 12-month period. The ioveraº system is a drug-free treatment that relieves pain via cryoneurolysis, a process whereby focused cold therapy is applied to a targeted nerve, temporarily interrupting its ability to transmit pain signals. Pain relief is typically experienced immediately after treatment, with the effects lasting up to 90 days as the nerve gradually regenerates. CLBP is the leading cause of disability in the U.S. and a major driver of opioid use, with facet-mediated pain representing up to 45% of cases. RFA, a standard interventional treatment, uses heat to destroy targeted nerves but can damage nearby tissue underscoring the need for alternative, tissue-sparing approaches like cryoneurolysis. The unblinded, single-center pilot study evaluated patients with facet-mediated CLBP who were randomized to receive either iovera° cryoneurolysis or RFA. Baseline characteristics, including pain scores, BMI, pain duration, and disability were similar between groups. Key Published Findings: Patients treated with iovera° experienced significantly lower pain scores at both 180 and 360 days compared with those treated with RFA Day 180: 3.1 vs. 5.4 (p=0.01)Day 360: 3.0 vs 6.1 (p=0.01) Functional disability improved more substantially with iovera°, with Oswestry Disability Index (ODI) scores significantly lower at 360 days Day 360: 10.1 vs 20.6 (p=0.002) Fewer iovera° patients required additional spine injections after 180 days 45.5% of iovera° patients vs. 75% of RFA patients ne...